Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

l be presented at an upcoming medical meeting, along with additional efficacy data from the 240 mg/day and lower dose groups. Final selection of the Phase 3 dose will be made following completion of data analyses.

"We are pleased to have reached another development milestone in our prostate cancer program by successfully completing enrollment in our Phase 1-2 clinical trial in castration-resistant prostate cancer patients with limited treatment options," said Lynn Seely, M.D., chief medical officer of Medivation. "We look forward to presenting additional data from this trial and to advancing this program into Phase 3 development in 2009, as we have previously guided."

About Prostate Cancer and MDV3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to de
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)....J., Nov. 25 Pharmasset,...tical company committed to discovering, developing...fections, reported financial results for the fisca...2009 Pharmasset held $58.4 million in cash, cash e...eline Update and 2009 Highlights ,, RG7128 ,...
(Date:11/25/2009)...EACH, Fla., Nov. 25 For ..., especially the 27 million living with untreated ...appy, says audiologist Cindy Beyer. ,, Dr. Beye... one of America,s largest hearing care and hearin...g loss to stress, frustration, and social isolatio...
(Date:11/25/2009)...K, Nov. 25 Reportlinker.com announ... in its catalogue: ,, United States Dental Dev... http://www.reportlinker.com/p0158733/United-State...2015.html ,, United States Dental Devices Mark...,, This report is an essential source for in-de...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Exposure to Common Pollutant in Womb Might Lower IQ 52093 1Exposure to Common Pollutant in Womb Might Lower IQ 52093 2Exposure to Common Pollutant in Womb Might Lower IQ 52093 3The Leukemia 26 Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 52091 1The Leukemia 26 Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 52091 2The Leukemia 26 Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 52091 3Mylan Declares Quarterly Preferred Stock Dividend 52089 1
...ta Include Results from Phase 1 Studies with Monoc...clinical Data Provide Further,Rationale for IL-9 I..., GAITHERSBURG, Md., May 24, 2007 /PRNewswire-Firs...entation of data,highlighting recent progress with...cluding results from two Phase 1 clinical,studies ...
...HAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- Wit...ceutical product at play,pharmaceutical firms nee...g clinical trial results early. Companies that mas...l gain a significant,advantage in the marketplace....Practices, LLC,successful companies create commun...
Other Medicine Technology:MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
(Date:11/28/2009)...ds gene variation believed to affect circadian rhy... News) -- New research suggests that an internal b... in the development of bipolar disorder in childre...of the genetic makeup of 152 children with bipolar...jor mood swings, and 140 children without the diso...
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall/...ny"), a supplier of precision technology products ... annual meeting of the Company,s shareholders has ...me and location of the meeting will be announced i...y received a requisition notice from Stephen Bersh...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today...1 virus genomic data. It shows that the lethality...d. 4.5) during the virus,s current outbreak in the...s week of 2.0 (s.d. 0.1). The H1N1 infectivity cou... Boston (PRWEB) November 27, 2009 -- Biote...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 ...ed that Blair Lambert, CFO/COO, will present at th...held at the May Fair Hotel in London, England, on ..., To listen to a live broadcast of The Gymboree ...se log on to www.gymboree.com, click on "Our Compa...
(Date:11/27/2009)..., NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewswir...rofessional cycling team dedicated to ethical spor... champions, announced today that it will become Te...ions Optical as a new sponsor of the team. Transit...f adaptive eyewear, offering the most advanced pho...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3
...or lose it, principle at work, one expert says , ...uent sexual intercourse may cut down on a man,s ch...researchers report. , "This is the same as any oth...ssor of urology at UMDNJ New Jersey Medical School...
...., July 3 The Minnesota Nurses,Association (MNA) ...berg in,his candidacy for U.S. House of Representa...erg made it clear to us he shares a guiding princi...tee,Chair, Tom Kelly, RN. "With his unequivocal su...
... aimed at adults, but Australian team says these 3...HealthDay News) -- A series of tests that are the ...aste and smell have been developed by Australian r...rmined that most children ages 5 to 7 can identify...
...D In response to the global health crisis, 26 lea...tion movements in global health promotion, health ...t week on what should comprise the domains of core...l University of Ireland, Galway, who serves as the...
...Death Syndrome (SIDS) is a condition that unexpect...y healthy babies aged between a month and a year. ...Laboratory in Monterotondo, Italy, have developed ...odel, published in this week,s issue of Science ,...
... Renowned, Italian, orthopaedic surgeon, ... American Orthopaedic Society for Sports Medicine ...M’s Annual Meeting in Orlando. , ...rican Orthopaedic Society for Sports Medicine (AO...
Other Medicine News:Health News:Lots of Sex May Prevent Erectile Dysfunction 2Health News:Minnesota Nurses Association Endorses Elwyn Tinklenberg for Congress 2Health News:Accord on core competency, standards and quality assurance in health promotion and education 2Health News:New research sheds light on the molecular basis of crib death 2Health News:Paolo Aglietti, MD, President of the International Society of Knee Surgery and Arthroscopy, Inducted into Sports Medicine Hall of Fame 2
2100 Pulse Oximeter
Resolve® Immersion Oil
Immersion Oil, BTL
Immersion oil UV-transparent
Medicine Products: